DiaMedica Therapeutics Inc. Common Stock/DMAC
$3.12
-3.99%-
1D1W1MYTD1YMAX
About DiaMedica Therapeutics Inc. Common Stock
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate DM199 (rinvecalinase alfa) is the first pharmaceutically active recombinant (synthetic) form of the human tissue kallikrein-1 (KLK1) protein to be clinically studied in patients. KLK1 is an established therapeutic modality in Asia, with human urinary KLK1, for the treatment of acute ischemic stroke and cardio renal disease, including hypertension. It has also produced a potential novel treatment for severe inflammatory diseases, DM300, which is in the early preclinical stage of development. KLK1 is a serine protease, or protein, produced primarily in the kidneys, pancreas and salivary glands. KLK1 plays a critical role in the regulation of local blood flow and vasodilation in the body, as well as an important role in reducing inflammation and oxidative stress.
Ticker
DMAC
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
CEO
Rick Pauls
Employees
18
Headquarters
Minneapolis, United States
Website
www.diamedica.com
DMAC Metrics
BasicAdvanced
$132M
Market cap
-
P/E ratio
-$0.62
EPS
1.76
Beta
-
Dividend rate
Price and volume
Market cap
$132M
Beta
1.75537
52-week high
$4.75
52-week low
$1.58
Average daily volume
42K
Financial strength
Current ratio
19.266
Long term debt to equity
0.002
Total debt to equity
0.008
Management effectiveness
Return on assets (TTM)
-43.77%
Return on equity (TTM)
-46.77%
Return on investment (TTM)
-46.37%
Valuation
Price to book
2.58
Price to tangible book (TTM)
2.58
Growth
Earnings per share change (TTM)
-19.27%
What the Analysts think about DMAC
Analyst Ratings
Majority rating from 3 analysts.
Price Targets
Average projection from 3 analysts.
High $8.00
Low $6.00
$3.12
Current price
$7.00
Average price target
DMAC Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
NaN%
Net income
-$5.1M
15.91%
Profit margin
0%
NaN%
DMAC Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.16
-$0.12
-$0.14
-$0.14
-
Expected
-$0.18
-$0.13
-$0.14
-$0.16
-$0.17
Surprise
-9.43%
-5.26%
0%
-10.64%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Upcoming events
FAQs
What’s the current market cap for DiaMedica Therapeutics Inc. Common Stock stock?
DiaMedica Therapeutics Inc. Common Stock (DMAC) has a market cap of $132M as of May 10, 2024.
What is the P/E ratio for DiaMedica Therapeutics Inc. Common Stock stock?
The price to earnings (P/E) ratio for DiaMedica Therapeutics Inc. Common Stock (DMAC) stock is 0 as of May 10, 2024.
Does DiaMedica Therapeutics Inc. Common Stock stock pay dividends?
No, DiaMedica Therapeutics Inc. Common Stock (DMAC) stock does not pay dividends to its shareholders as of May 10, 2024.
When is the next DiaMedica Therapeutics Inc. Common Stock dividend payment date?
DiaMedica Therapeutics Inc. Common Stock (DMAC) stock does not pay dividends to its shareholders.
What is the beta indicator for DiaMedica Therapeutics Inc. Common Stock?
DiaMedica Therapeutics Inc. Common Stock (DMAC) has a beta rating of 1.76. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
What is the DiaMedica Therapeutics Inc. Common Stock stock price target?
The target price for DiaMedica Therapeutics Inc. Common Stock (DMAC) stock is $7, which is 124.36% above the current price of $3.12. This is an average based on projections from 3 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.
Buy or sell DiaMedica Therapeutics Inc. Common Stock stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.